This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
by Zacks Equity Research
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.
How to Play NVO Stock After New Drug's Success in Obesity Study
by Ahan Chakraborty
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.
Here's How to Play Pfizer Stock Before Q4 Earnings Release
by Kinjel Shah
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
First FOMC Meeting of 2025: Global Week Ahead
by John Blank
The central bank is widely expected to pause its easing cycle on Wednesday, after cuts totaling 100 basis points (bps) last year.
NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
by Zacks Equity Research
Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to placebo in an obesity study.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
by Zacks Equity Research
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
by Ahan Chakraborty
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
Company News for Jan 21, 2025
by Zacks Equity Research
Companies In The Article Are: INTC, NVO, VST, JBHT
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
by Zacks Equity Research
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
Company News for Jan 20, 2025
by Zacks Equity Research
Companies In The Article Are: INTC, NVO, VST, JBHT
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
by Sundeep Ganoria
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
by Zacks Equity Research
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, Novo Nordisk (NVO) closed at $84.62, indicating a -1.9% shift from the previous trading day.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
by Kinjel Shah
FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
by Shaun Pruitt
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
by Zacks Equity Research
Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
LLY Falls Around 14% in 3 Months: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?